BriaCell Therapeutics Corp. (BCTX)
NASDAQ: BCTX · Real-Time Price · USD
4.060
+0.030 (0.74%)
At close: Apr 28, 2026, 4:00 PM EDT
3.990
-0.070 (-1.72%)
After-hours: Apr 28, 2026, 6:55 PM EDT
BriaCell Therapeutics Income Statement
Financials in millions USD. Fiscal year is August - July.
Millions USD. Fiscal year is Aug - Jul.
| TTM
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Jan '26 Jan 31, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 |
| Selling, General & Admin | 6.56 | 6.39 | 6.57 | 8.51 | 7.58 | 4.96 | |
| Research & Development | 24.17 | 20.81 | 26.76 | 14.76 | 7.71 | 2.02 | |
| Operating Expenses | 30.74 | 27.2 | 33.33 | 23.27 | 15.29 | 6.98 | |
| Operating Income | -30.74 | -27.2 | -33.33 | -23.27 | -15.29 | -6.98 | |
| Interest Expense | -0.04 | -0.04 | - | - | -0 | -0.08 | |
| Interest & Investment Income | 0.3 | 0.12 | 0.29 | 0.89 | 0.14 | 0 | |
| Earnings From Equity Investments | -0.22 | -0.22 | -0.11 | - | - | - | |
| Currency Exchange Gain (Loss) | -0.04 | -0.02 | -0.03 | -0.04 | -0.03 | -2.18 | |
| Other Non Operating Income (Expenses) | 0.71 | 0.76 | 28.24 | 2.12 | -11.65 | -4.45 | |
| EBT Excluding Unusual Items | -30.02 | -26.61 | -4.93 | -20.3 | -26.84 | -13.67 | |
| Gain (Loss) on Sale of Investments | 0.06 | 0.06 | - | - | - | - | |
| Other Unusual Items | - | - | - | - | - | -0.14 | |
| Pretax Income | -29.96 | -26.56 | -4.93 | -20.3 | -26.84 | -13.82 | |
| Earnings From Continuing Operations | -29.96 | -26.56 | -4.93 | -20.3 | -26.84 | -13.82 | |
| Minority Interest in Earnings | 0.33 | 0.24 | 0.14 | - | - | - | |
| Net Income | -29.64 | -26.31 | -4.79 | -20.3 | -26.84 | -13.82 | |
| Net Income to Common | -29.64 | -26.31 | -4.79 | -20.3 | -26.84 | -13.82 | |
| Shares Outstanding (Basic) | 1 | 0 | 0 | 0 | 0 | 0 | |
| Shares Outstanding (Diluted) | 1 | 0 | 0 | 0 | 0 | 0 | |
| Shares Change (YoY) | 784.70% | 285.70% | 5.35% | 0.81% | 242.82% | - | |
| EPS (Basic) | -19.98 | -62.19 | -43.68 | -194.97 | -259.83 | -458.54 | |
| EPS (Diluted) | -19.98 | -62.19 | -43.68 | -194.97 | -259.83 | -458.54 | |
| Free Cash Flow | -30.97 | -28.17 | -24.58 | -23.74 | -12.48 | -7.75 | |
| Free Cash Flow Per Share | -20.88 | -66.58 | -224.09 | -228.03 | -120.86 | -257.22 | |
| EBITDA | -30.63 | -27.1 | -33.25 | -23.26 | -15.27 | -6.96 | |
| D&A For EBITDA | 0.11 | 0.11 | 0.08 | 0.02 | 0.02 | 0.02 | |
| EBIT | -30.74 | -27.2 | -33.33 | -23.27 | -15.29 | -6.98 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.